Burzynski Research Institute, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BZYR research report →
Companywww.burzynskiclinic.com
Burzynski Research Institute, Inc. engages in the research and development of antineoplaston drugs to treat cancer. The company is also involved in the production, marketing, promotion, and sale of medical chemical compounds composed of growth-inhibiting peptides, amino acid derivatives, and organic acids under the Antineoplastons trade name.
- CEO
- Stanislaw R. Burzynski
- IPO
- 1997
- Employees
- 1
- HQ
- Houston, TX, US
Price Chart
Valuation
- Market Cap
- $1.45M
- P/E
- -1.12
- P/S
- 0.00
- P/B
- -21.47
- EV/EBITDA
- -0.87
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 2073.54%
- ROIC
- 1911.08%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-1,386,207 · -3.80%
- EPS
- $-0.01 · -2.94%
- Op Income
- $-1,386,207
- FCF YoY
- 25.82%
Performance & Tape
- 52W High
- $0.06
- 52W Low
- $0.01
- 50D MA
- $0.02
- 200D MA
- $0.03
- Beta
- 0.28
- Avg Volume
- 7.74K
Get TickerSpark's AI analysis on BZYR
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our BZYR Coverage
We haven't published any research on BZYR yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate BZYR Report →